Clarius brings ultrasounds to your smartphone

Clarius Mobile Health, manufacturers of digital healthcare devices, has introduced a portable ultrasound scanner that is utilized through a smartphone.

The Clarius C3 scanner works on both iOS and Android devices, making the wireless device portable without wires or additional equipment. Designed for ultrasonic images of the lung and abdomen, the devices give real time images right at the bedside of patients. The scanner is made with a magnesium case for easy sterilization and uses a rechargeable battery.

The Clarius C3 is designed to image the lungs and abdomen. It incorporates a virtual phased array for quick scans of the heart.

"Lung ultrasound has been shown in different studies to be a better test for numerous types of lung pathologies than a chest x-ray and sometimes even better than a CT scan," said Shane Arishenkoff, MD, an internal medicine physician in Vancouver. "It gives me the ability to get real-time patient information rather than waiting for results.  After initiating treatment, I can go back to the patient to see if my therapies are helping. Unlike many new ultrasound machines, Clarius is ideal for lung scanning because it uses a unique imaging technology that provides excellent imaging, yet does not eliminate the artifacts that we need to scan the lung. It's also great not to have to deal with wires and cords."

Click here to watch a video featuring Arishenkoff

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.